

Appl. No. 10/582,893  
Amdt. Dated November 9, 2010  
Reply to Office Action of June 8, 2010

**Amendments to the Claims.**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended) A method of optical imaging of lung cancer of an animate subject involving administering a contrast agent to said subject and generating an optical image of at least a part of the subject to which said contrast agent has distributed, wherein said contrast agent has a molecular weight below 14,000 Daltons, and is of formula I:



wherein

V is one or more vector moieties having affinity for an abnormally expressed target in lung cancer, said target ~~is being chosen from~~ HER2/epidermal growth factor receptor (EGFR),  
~~wherein V is a tyrosine kinase inhibitor for the tyrosine kinase of EGFR;~~

L is a linker moiety or a bond; and

R is one or more reporter moieties detectable in optical imaging, wherein the reporter characteristics do not change upon binding of said contrast agent to said target.

2. (Cancelled)

3. (Cancelled)

4. (Cancelled)

5. (Cancelled)

6. (Previously presented) The method as claimed in claim 1 wherein V is selected from peptides, peptoid moieties, oligonucleotides, oligosaccharides, fat-related compounds and traditional organic drug-like small molecules.
7. (Previously presented) The method as claimed in claim 1 wherein R is a dye that interacts with light in the wavelength region from the ultraviolet to the near-infrared part of the electromagnetic spectrum.
8. (Previously presented) The method of claim 1, where the contrast agent is administered as a pharmaceutical composition, said composition comprising a contrast agent as defined in claim 1 together with at least one pharmaceutically acceptable carrier or excipient.
9. (Cancelled)
10. (Cancelled)
11. (Previously presented) The method as claimed in claim 1 wherein the optical imaging is for the diagnosis of lung cancer, for the follow up of the progress of lung cancer development, for the follow up of treatment of lung cancer or for surgical guidance.
12. (Cancelled)
13. (Cancelled)